Nerve function impairment in leprosy at diagnosis and at completion of MDT: A retrospective cohort study of 786 patients in Bangladesh

Leprosy Review

Volumn 67, Issue 4, 1996, Pages 297-305

  Richardus, J H ^a   Finlay, K M ^a   Croft, R P ^a   Smith, W C S ^b  

^a Danish Bangladesh Leprosy Mission   (Bangladesh)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEPROSTATIC AGENT; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; BANGLADESH; CHILD; DISEASE CLASSIFICATION; FEMALE; HUMAN; INFANT; LEPROSY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PERIPHERAL NEUROPATHY; POSTERIOR TIBIAL NERVE; RETROSPECTIVE STUDY; ULNAR NERVE; WORLD HEALTH ORGANIZATION;

EID: 0030498842     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: 10.5935/0305-7518.19960030     Document Type: Article

References (11)

1. Srinivasan H. Deformities and disabilities - unfinished agenda in leprosy work. Lepr Rev, 1995; 66: 193-200.
2. Lienhardt C, Fine PEM. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev, 1994; 65: 9-33.
3. Van Brakel WH. Peripheral neuropathy in leprosy. The continuing challenge. Thesis Universiteit Utrecht, 1994.
4. Richardus JH, Croft RP. Estimating the size of the leprosy problem: the Bangladesh experience. Lepr Rev, 1995; 66: 158-64.
5. Watson JM. Essential action to minimise disability in leprosy patients. The Leprosy Mission International. London, 1988.
6. Van Brakel WH, Khawas IB. Nerve damage in leprosy: an epidemiological and clinical study of 396 patients in west Nepal - part 1. Definitions, methods and frequencies. Lepr Rev, 1994; 65: 204-221.
7. WHO Expert Committee on leprosy, sixth Report. WHO Technical Report series. No. 768. WHO, Geneva, 1988.
8. WHO. Weekly Epidemiological Record, 1995; 70: 269-76.
9. Van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. Lepr Rev, 1994; 65: 190-203.
10. Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the Leprosy Control Program of the All Africa Leprosy and Rehabilitation Training Centre (ALERT) in Ethiopia. Int J Lepr, 1992; 60: 173-84.
11. Roche PW, Theuvenet WJ, Britton WJ. Risk factors for type I reactions on borderline leprosy patients. Lancet, 1991: 338: 654-6.